High glucose induces senescence in synovial mesenchymal stem cells through mitochondrial dysfunction

被引:0
作者
Shuyi Tan [1 ]
Wangxi Wu [1 ]
Yifan Chen [1 ]
Hai Gao [1 ]
机构
[1] Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou
关键词
High glucose; Mitochondrial dysfunction; OA; Senescence; SMSCs;
D O I
10.1186/s12903-025-05938-y
中图分类号
学科分类号
摘要
Purpose: To investigate the impact of high glucose on the senescence of synovial mesenchymal stem cells (SMSCs) and to elucidate the role of mitochondrial dysfunction in this process. Methods: ‌SMSCs were treated with medium containing high glucose (25 mmol/L) or low glucose (5.5 mmol/L) concentrations. The effects of high glucose concentrations on the proliferation, senescence, mitochondrial reactive oxygen species (ROS) levels, mitochondrial fission, and mitophagy of SMSCs were investigated. First, the impact of 24-hour high glucose treatment on SMSCs was investigated‌. After this initial 24-hour exposure, the medium was subsequently changed to low glucose, and the cells were cultivated for an additional 24 h; this was then compared with the effects of continuous 48-hour high-glucose exposure and continuous 48-hour low-glucose exposure. Results: High glucose concentrations did not promote the proliferation of SMSCs but rather accelerated their senescence by ‌upregulating‌ the mRNA expression of senescence-associated secretory phenotype (SASP) genes and increasing the number of senescence-associated β-galactosidase (SA-β-gal)-positive cells. Additionally, high glucose ‌concentrations elevated‌ ROS levels in mitochondria and ‌facilitated‌ mitochondrial fission; they also ‌inhibited‌ the mitophagy of SMSCs by suppressing the expression of mitophagy-related proteins (PINK1, PARKIN, and LC3B). High glucose-induced suppression of mRNA (Il-6, Cxcl1, Dnm1, Pink1, Prkn, Lc3b) and protein (P21) expression, along with increased SA-β-gal-positive cell numbers and elevated MitoSOX intensity, can be reversed by terminating the high glucose treatment. Conclusion: High glucose concentrations induce senescence in SMSCs via mitochondrial dysfunction, manifested as ROS accumulation, excessive fission, and mitophagy suppression. Glucose normalization reversed senescence phenotypes, accompanied by restored mitophagy and reduced oxidative stress. Mitochondrial dysfunction may be one of the key mechanisms underlying high glucose-induced senescence in SMSCs. © The Author(s) 2025.
引用
收藏
相关论文
共 33 条
  • [1] Hunter D.J., Bierma-Zeinstra S., Osteoarthritis, Lancet, 393, pp. 1745-1759, (2019)
  • [2] Giorgino R., Albano D., Fusco S., Peretti G.M., Mangiavini L., Messina C., Knee osteoarthritis: epidemiology, pathogenesis, and mesenchymal stem cells: what else is new? An update, Int J Mol Sci, 24, 7, (2023)
  • [3] Wu J.H., Chen H.B., Wu Y.Q., Wu Y., Wang Z.J., Wu T., Wang M.Y., Wang S.Y., Wang X.W., Wang J.T., Et al., [Prevalence and risk factors of osteoarthritis in patients with type 2 diabetes in Beijing, China from 2015 to 2017], Beijing Da Xue Xue Bao Yi Xue Ban, 53, 3, pp. 518-522, (2021)
  • [4] Rios-Arce N.D., Hum N.R., Loots G.G., Interactions between diabetes mellitus and osteoarthritis: from animal studies to clinical data, JBMR Plus, 6, 5, (2022)
  • [5] Veronese N., Cooper C., Reginster J.Y., Hochberg M., Branco J., Bruyere O., Chapurlat R., Al-Daghri N., Dennison E., Herrero-Beaumont G., Et al., Type 2 diabetes mellitus and osteoarthritis, Semin Arthritis Rheum, 49, 1, pp. 9-19, (2019)
  • [6] Zhu C., Wu W., Qu X., Mesenchymal stem cells in osteoarthritis therapy: a review, Am J Transl Res, 13, 2, pp. 448-461, (2021)
  • [7] Ullah I., Subbarao R.B., Rho G.J., Human mesenchymal stem cells - current trends and future prospective, Biosci Rep, 35, 2, (2015)
  • [8] Jeyaraman M., Muthu S., Jeyaraman N., Ranjan R., Jha S.K., Mishra P., Synovium derived mesenchymal stromal cells (Sy-MSCs): A promising therapeutic paradigm in the management of knee osteoarthritis, Indian J Orthop, 56, 1, pp. 1-15, (2022)
  • [9] Kohnke R., Ahlers M.O., Birkelbach M.A., Ewald F., Krueger M., Fiedler I., Busse B., Heiland M., Vollkommer T., Gosau M., Et al., Temporomandibular joint osteoarthritis: regenerative treatment by a stem cell containing advanced therapy medicinal product (ATMP)-An in vivo animal trial, Int J Mol Sci, 22, 1, (2021)
  • [10] Matheus H.R., Ozdemir S.D., Guastaldi F.P.S., Stem cell-based therapies for temporomandibular joint osteoarthritis and regeneration of cartilage/osteochondral defects: a systematic review of preclinical experiments, Osteoarthritis Cartilage, 30, 9, pp. 1174-1185, (2022)